Shopping Cart

Your shopping cart is currently empty

Carrageenan

Name: Carrageenan
Brand: TargetMol
SKU: T35327
Price: 40 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: kappa-Carrageenan) Copy Product Info

🥰Excellent

Synonyms: kappa-Carrageenan

Catalog No. T35327 Copy Product Info

🥰Excellent

Carrageenan (kappa-Carrageenan) is a naturally occurring polysaccharide extracted from edible red seaweed species. Carrageenan exhibits anticoagulant, antithrombotic, antiviral, antitumor, and immunomodulatory activities. Carrageenan is extensively utilized in biomedical and immunological research involving inflammation, coagulation pathways, viral interaction mechanisms, and polysaccharide-based biomaterial development.

Carrageenan

Cas No. 9000-07-1

Pack Size	Price	USA Stock	Global Stock	Quantity
25 g	$40	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Appearance:Solid

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Carrageenan (kappa-Carrageenan) is a naturally occurring polysaccharide extracted from edible red seaweed species. Carrageenan exhibits anticoagulant, antithrombotic, antiviral, antitumor, and immunomodulatory activities. Carrageenan is extensively utilized in biomedical and immunological research involving inflammation, coagulation pathways, viral interaction mechanisms, and polysaccharide-based biomaterial development.
In vitro	ι-Carrageenan, λ-Carrageenan, and κ-Carrageenan (0.5–200 μg/mL, 15 d) inhibit HAV antigen expression in PLC/PRF/5 cells in a concentration-dependent manner, with ι-Carrageenan displaying the highest potency with ED50 value of 2.5 μg/mL, followed by λ-Carrageenan (ED50 = 4.5 μg/mL) and κ-Carrageenan (ED50 = 100.3 μg/mL); concomitantly, all three Carrageenans also suppress HAV replication and infectivity in PLC/PRF/5 cells in a concentration-dependent manner. [1] ι-Carrageenan, λ-Carrageenan and κ-Carrageenan (20–1000 μg/mL, 3–15 d) show no significant cytotoxicity at concentrations up to 200 μg/mL in PLC/PRF/5 cells. With respect to cytotoxicity, ι-Carrageenan and λ-Carrageenan exhibit higher cytotoxicity thresholds (cell viability CD50 >1000 μg/mL) than κ-Carrageenan, for which the cell viability CD50 is 732.1 μg/mL[1]. κ-Carrageenan and λ-Carrageenan (250-2500 μg/mL, 72 h) exhibit moderate concentration-dependent cytotoxicity against HeLa cells with IC50 value of 550.8 μg/mL and 475 μg/mL, respectively[2]. κ-Carrageenan (250-2500 μg/mL, 72 h) causes G2/M phase arrest in HeLa-FUCCI cells in a concentration-dependent manner, whereas λ-co does not change the distribution of cell cycle phases in HeLa-FUCCI cells[2]. κ-Carrageenan and λ-Carrageenan (250-2500 μg/mL, 72 h) hardly has significant cytotoxicity toward HUVEC cells at concentrations and do not increase HUVEC cell mortality[2].
In vivo	Carrageenan (1% (w/v); s.c.; plantar region of the left hind paw) induces acute paw edema in male Wistar rats at an injection volume of 100 μL and the peak edema volume reached 4-5 hours post-injection[3]. Carrageenan (1% (w/v); s.c.; plantar region of the left hind paw) induces acute paw edema in male Swiss albino mice at an injection volume of 25 μL[3].
Synonyms	kappa-Carrageenan

Chemical Properties

Cas No.

9000-07-1

Storage & Solubility Information

Storage	Keep away from direct sunlight, Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	H2O: 2.66 mg/mL, Sonication is recommended.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc